Login Register Cart 0
Generic placeholder image

Current Cardiology Reviews

Editor-in-Chief

ISSN (Print): 1573-403X
ISSN (Online): 1875-6557

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Beyond Ejection Fraction: Novel Clinical Approaches Towards Sudden Cardiac Death Risk Stratification in Patients with Dilated Cardiomyopathy

Author(s): Issa Pour-Ghaz, Mark Heckle, Ikechukwu Ifedili, Sharif Kayali, Christopher Nance, Rajesh Kabra, Sunil K. Jha, John L. Jefferies and Yehoshua C. Levine*

Volume 18, Issue 2, 2022

Published on: 04 August, 2021

Article ID: e040821195265 Pages: 9

DOI: 10.2174/1573403X17666210804125939

Price: $65

Abstract

Implantable Cardioverter-Defibrillator (ICD) therapy is indicated for patients at risk for sudden cardiac death due to ventricular tachyarrhythmia. The most commonly used risk stratification algorithms use Left Ventricular Ejection Fraction (LVEF) to determine which patients qualify for ICD therapy, even though LVEF is a better marker of total mortality than ventricular tachyarrhythmias mortality. This review evaluates imaging tools and novel biomarkers proposed for better risk stratifying arrhythmic substrate, thereby identifying optimal ICD therapy candidates.

Keywords: Sudden cardiac death, risk stratification, cardiac MRI, biomarkers, left ventricular ejection fraction, implantable cardioverter defibrillator.

Graphical Abstract

[1]
van der Bijl P, Delgado V, Bax JJ. Imaging for sudden cardiac death risk stratification: Current perspective and future directions. Prog Cardiovasc Dis 2019; 62(3): 205-11.
[http://dx.doi.org/10.1016/j.pcad.2019.04.005] [PMID: 31054859]
[2]
Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346(12): 877-83.
[http://dx.doi.org/10.1056/NEJMoa013474] [PMID: 11907286]
[3]
Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352(3): 225-37.
[http://dx.doi.org/10.1056/NEJMoa043399] [PMID: 15659722]
[4]
Kadish A, Dyer A, Daubert JP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004; 350(21): 2151-8.
[http://dx.doi.org/10.1056/NEJMoa033088] [PMID: 15152060]
[5]
Køber L, Thune JJ, Nielsen JC, et al. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med 2016; 375(13): 1221-30.
[http://dx.doi.org/10.1056/NEJMoa1608029] [PMID: 27571011]
[6]
van der Bijl P, Delgado V, Bax JJ. Sudden cardiac death: The role of imaging. Int J Cardiol 2017; 237: 15-8.
[http://dx.doi.org/10.1016/j.ijcard.2017.03.010] [PMID: 28284506]
[7]
Di Marco A, Anguera I, Schmitt M, et al. Late gadolinium enhancement and the risk for ventricular arrhythmias or sudden death in dilated cardiomyopathy: Systematic review and meta-analysis. JACC Heart Fail 2017; 5(1): 28-38.
[http://dx.doi.org/10.1016/j.jchf.2016.09.017] [PMID: 28017348]
[8]
Disertori M, Rigoni M, Pace N, et al. Myocardial fibrosis assessment by lge is a powerful predictor of ventricular tachyarrhythmias in ischemic and nonischemic lv dysfunction: A meta-analysis. JACC Cardiovasc Imaging 2016; 9(9): 1046-55.
[http://dx.doi.org/10.1016/j.jcmg.2016.01.033] [PMID: 27450871]
[9]
Blankstein R, Osborne M, Naya M, et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol 2014; 63(4): 329-36.
[http://dx.doi.org/10.1016/j.jacc.2013.09.022] [PMID: 24140661]
[10]
Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the american college of cardiology/american heart association task force on clinical practice guidelines and the heart rhythm society. Circulation 2018; 138(13): e272-391.
[http://dx.doi.org/10.1161/CIR.0000000000000549] [PMID: 29084731]
[11]
Al-Khatib SM, Fonarow GC, Joglar JA, et al. Primary prevention implantable cardioverter defibrillators in patients with nonischemic cardiomyopathy: A meta-analysis. JAMA Cardiol 2017; 2(6): 685-8.
[http://dx.doi.org/10.1001/jamacardio.2017.0630] [PMID: 28355432]
[12]
Gorgels AP, Gijsbers C, de Vreede-Swagemakers J, Lousberg A, Wellens HJ. Out-of-hospital cardiac arrest-the relevance of heart failure. The maastricht circulatory arrest registry. Eur Heart J 2003; 24(13): 1204-9.
[http://dx.doi.org/10.1016/S0195-668X(03)00191-X] [PMID: 12831814]
[13]
Stecker EC, Vickers C, Waltz J, et al. Population-based analysis of sudden cardiac death with and without left ventricular systolic dysfunction: two-year findings from the Oregon Sudden Unexpected Death Study. J Am Coll Cardiol 2006; 47(6): 1161-6.
[http://dx.doi.org/10.1016/j.jacc.2005.11.045] [PMID: 16545646]
[14]
Buxton AE, Lee KL, Hafley GE, et al. Relation of ejection fraction and inducible ventricular tachycardia to mode of death in patients with coronary artery disease: An analysis of patients enrolled in the multicenter unsustained tachycardia trial. Circulation 2002; 106(19): 2466-72.
[http://dx.doi.org/10.1161/01.CIR.0000037224.15873.83] [PMID: 12417544]
[15]
de Haas HJ, Arbustini E, Fuster V, Kramer CM, Narula J. Molecular imaging of the cardiac extracellular matrix. Circ Res 2014; 114(5): 903-15.
[http://dx.doi.org/10.1161/CIRCRESAHA.113.302680] [PMID: 24577969]
[16]
Spinale FG. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev 2007; 87(4): 1285-342.
[http://dx.doi.org/10.1152/physrev.00012.2007] [PMID: 17928585]
[17]
Vasquez C, Benamer N, Morley GE. The cardiac fibroblast: functional and electrophysiological considerations in healthy and diseased hearts. J Cardiovasc Pharmacol 2011; 57(4): 380-8.
[http://dx.doi.org/10.1097/FJC.0b013e31820cda19] [PMID: 21242811]
[18]
Bagchi RA, Roche P, Aroutiounova N, et al. The transcription factor scleraxis is a critical regulator of cardiac fibroblast phenotype. BMC Biol 2016; 14(1): 21.
[http://dx.doi.org/10.1186/s12915-016-0243-8] [PMID: 26988708]
[19]
Weber KT, Sun Y, Bhattacharya SK, Ahokas RA, Gerling IC. Myofibroblast-mediated mechanisms of pathological remodelling of the heart. Nat Rev Cardiol 2013; 10(1): 15-26.
[http://dx.doi.org/10.1038/nrcardio.2012.158] [PMID: 23207731]
[20]
Nguyen MN, Kiriazis H, Gao XM, Du XJ. Cardiac fibrosis and arrhythmogenesis. Compr Physiol 2017; 7(3): 1009-49.
[http://dx.doi.org/10.1002/cphy.c160046] [PMID: 28640451]
[21]
de Boer RA, De Keulenaer G, Bauersachs J, et al. Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology. Eur J Heart Fail 2019; 21(3): 272-85.
[http://dx.doi.org/10.1002/ejhf.1406] [PMID: 30714667]
[22]
Josephson ME, Horowitz LN, Farshidi A, Kastor JA. Recurrent sustained ventricular tachycardia. 1. Mechanisms. Circulation 1978; 57(3): 431-40.
[http://dx.doi.org/10.1161/01.CIR.57.3.431] [PMID: 624152]
[23]
Shah SJ, Kitzman DW, Borlaug BA, et al. Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap. Circulation 2016; 134(1): 73-90.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.116.021884] [PMID: 27358439]
[24]
Nguyen TP, Qu Z, Weiss JN. Cardiac fibrosis and arrhythmogenesis: the road to repair is paved with perils. J Mol Cell Cardiol 2014; 70: 83-91.
[http://dx.doi.org/10.1016/j.yjmcc.2013.10.018] [PMID: 24184999]
[25]
Morita N, Mandel WJ, Kobayashi Y, Karagueuzian HS. Cardiac fibrosis as a determinant of ventricular tachyarrhythmias. J Arrhythm 2014; 30(6): 389-94.
[http://dx.doi.org/10.1016/j.joa.2013.12.008] [PMID: 25642299]
[26]
Porcari A, De Luca A, Grigoratos C, et al. Arrhythmic risk stratification by cardiac magnetic resonance tissue characterization: disclosing the arrhythmic substrate within the heart muscle. Heart Fail Rev 2020.
[http://dx.doi.org/10.1007/s10741-020-09986-0] [PMID: 32564329]
[27]
Peters NS, Wit AL. Myocardial architecture and ventricular arrhythmogenesis. Circulation 1998; 97(17): 1746-54.
[http://dx.doi.org/10.1161/01.CIR.97.17.1746] [PMID: 9591770]
[28]
Becker MAJ, Cornel JH, van de Ven PM, van Rossum AC, Allaart CP, Germans T. The prognostic value of vate gadolinium-enhanced cardiac magnetic resonance imaging in nonischemic dilated cardiomyopathy: A review and meta-analysis. JACC Cardiovasc Imaging 2018; 11(9): 1274-84.
[http://dx.doi.org/10.1016/j.jcmg.2018.03.006] [PMID: 29680351]
[29]
Halliday BP, Cleland JGF, Goldberger JJ, Prasad SK. Personalizing sudden death risk stratification in dilated cardiomyopathy: Past, present and future. Circulation 2017; 136: 215-31.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.116.027134] [PMID: 28696268]
[30]
Halliday BP, Gulati A, Ali A, et al. Association between midwall late gadolinium enhancement and sudden cardiac death in patients with dilated cardiomyopathy and mild and moderate left ventricular systolic dysfunction. Circulation 2017; 135(22): 2106-15.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.116.026910] [PMID: 28351901]
[31]
Puntmann VO, Carr-White G, Jabbour A, et al. T1-mapping and outcome in nonischemic cardiomyopathy: All-cause mortality and heart failure. JACC Cardiovasc Imaging 2016; 9(1): 40-50.
[http://dx.doi.org/10.1016/j.jcmg.2015.12.001] [PMID: 26762873]
[32]
Bogun FM, Desjardins B, Good E, et al. Delayed-enhanced magnetic resonance imaging in nonischemic cardiomyopathy: utility for identifying the ventricular arrhythmia substrate. J Am Coll Cardiol 2009; 53(13): 1138-45.
[http://dx.doi.org/10.1016/j.jacc.2008.11.052] [PMID: 19324259]
[33]
Vita T, Gräni C, Abbasi SA, et al. Comparing cmr mapping methods and myocardial patterns toward heart failure outcomes in nonischemic dilated cardiomyopathy. JACC Cardiovasc Imaging 2019; 12(8 Pt 2): 1659-69.
[http://dx.doi.org/10.1016/j.jcmg.2018.08.021] [PMID: 30448130]
[34]
Li X, Fan X, Li S, et al. A novel risk stratification score for sudden cardiac death prediction in middle-aged, nonischemic dilated cardiomyopathy patients: the estimated score. Can J Cardiol 2020; 36(7): 1121-9.
[http://dx.doi.org/10.1016/j.cjca.2019.11.009] [PMID: 32249067]
[35]
Selvanayagam J, Prasad SK, M. Gavigan AD, et al. Cardiac magnetic resonance guided management of mild-moderate left ventricular systolic dysfunction. CMR-guide J Cardiovas Res 2015; 17(1): 1-2.
[36]
Berk BC, Fujiwara K, Lehoux S. ECM remodeling in hypertensive heart disease. J Clin Invest 2007; 117(3): 568-75.
[http://dx.doi.org/10.1172/JCI31044] [PMID: 17332884]
[37]
Rodriguez-Pascual F, Slatter DA. Collagen cross-linking: insights on the evolution of metazoan extracellular matrix. Sci Rep 2016; 6(1): 37374.
[http://dx.doi.org/10.1038/srep37374] [PMID: 27876853]
[38]
Querejeta R, López B, González A, et al. Increased collagen type I synthesis in patients with heart failure of hypertensive origin: relation to myocardial fibrosis. Circulation 2004; 110(10): 1263-8.
[http://dx.doi.org/10.1161/01.CIR.0000140973.60992.9A] [PMID: 15313958]
[39]
Weber KT, Janicki JS, Shroff SG, Pick R, Chen RM, Bashey RI. Collagen remodeling of the pressure-overloaded, hypertrophied nonhuman primate myocardium. Circ Res 1988; 62(4): 757-65.
[http://dx.doi.org/10.1161/01.RES.62.4.757] [PMID: 2964945]
[40]
Melkko J, Niemi S, Risteli L, Risteli J. Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clin Chem 1990; 36(7): 1328-32.
[http://dx.doi.org/10.1093/clinchem/36.7.1328] [PMID: 2372946]
[41]
Yang C, Qiao S, Song Y, et al. Procollagen type I carboxy-terminal propeptide (PICP) and MMP-2 are potential biomarkers of myocardial fibrosis in patients with hypertrophic cardiomyopathy. Cardiovasc Pathol 2019; 43: 107150.
[http://dx.doi.org/10.1016/j.carpath.2019.107150] [PMID: 31639652]
[42]
Risteli J, Risteli L. Analysing connective tissue metabolites in human serum. Biochemical, physiological and methodological aspects. J Hepatol 1995; 22(2)(Suppl.): 77-81.
[PMID: 7665854]
[43]
Zile MR, O’Meara E, Claggett B, et al. Effects of sacubitril/valsartan on biomarkers of extracellular matrix regulation in patients with hFrEF. J Am Coll Cardiol 2019; 73(7): 795-806.
[http://dx.doi.org/10.1016/j.jacc.2018.11.042] [PMID: 30784673]
[44]
Zhang B, Li X, Chen C, et al. Renal denervation effects on myocardial fibrosis and ventricular arrhythmias in rats with ischemic cardiomyopathy. Cell Physiol Biochem 2018; 46(6): 2471-9.
[http://dx.doi.org/10.1159/000489653] [PMID: 29742489]
[45]
Medugorac I, Jacob R. Characterisation of left ventricular collagen in the rat. Cardiovasc Res 1983; 17(1): 15-21.
[http://dx.doi.org/10.1093/cvr/17.1.15] [PMID: 6221797]
[46]
Klappacher G, Franzen P, Haab D, et al. Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis. Am J Cardiol 1995; 75(14): 913-8.
[http://dx.doi.org/10.1016/S0002-9149(99)80686-9] [PMID: 7733000]
[47]
Lovelock JD, Baker AH, Gao F, et al. Heterogeneous effects of tissue inhibitors of matrix metalloproteinases on cardiac fibroblasts. Am J Physiol Heart Circ Physiol 2005; 288(2): H461-8.
[http://dx.doi.org/10.1152/ajpheart.00402.2004] [PMID: 15650153]
[48]
Xiao T, Zeng O, Luo J, Wu Z, Li F, Yang J. Effects of hydrogen sulfide on myocardial fibrosis in diabetic rats: Changes in matrix metalloproteinases parameters. Biomed Mater Eng 2015; 26(Suppl. 1): S2033-9.
[http://dx.doi.org/10.3233/BME-151508] [PMID: 26405980]
[49]
Frantz S, Störk S, Michels K, et al. Tissue inhibitor of metalloproteinases levels in patients with chronic heart failure: An independent predictor of mortality. Eur J Heart Fail 2008; 10(4): 388-95.
[http://dx.doi.org/10.1016/j.ejheart.2008.02.015] [PMID: 18343723]
[50]
van der Bijl P, Podlesnikar T, Bax JJ, Delgado V. Sudden cardiac death risk prediction: The role of cardiac magnetic resonance imaging. Rev Esp Cardiol (Engl Ed) 2018; 71(11): 961-70.
[http://dx.doi.org/10.1016/j.rec.2018.05.019] [PMID: 29970349]
[51]
Myerburg RJ, Mitrani R, Interian A Jr, Castellanos A. Interpretation of outcomes of antiarrhythmic clinical trials: design features and population impact. Circulation 1998; 97(15): 1514-21.
[http://dx.doi.org/10.1161/01.CIR.97.15.1514] [PMID: 9576433]
[52]
Marrow BA, Cook SA, Prasad SK, McCann GP. Emerging techniques for risk stratification in nonischemic dilated cardiomyopathy: Jacc review topic of the week. J Am Coll Cardiol 2020; 75(10): 1196-207.
[http://dx.doi.org/10.1016/j.jacc.2019.12.058] [PMID: 32164893]
[53]
van der Bijl P, Khidir MJH, Leung M, et al. Reduced left ventricular mechanical dispersion at 6 months follow-up after cardiac resynchronization therapy is associated with superior long-term outcome. Heart Rhythm 2018; 15(11): 1683-9.
[http://dx.doi.org/10.1016/j.hrthm.2018.05.005] [PMID: 29753023]
[54]
Haugaa KH, Goebel B, Dahlslett T, et al. Risk assessment of ventricular arrhythmias in patients with nonischemic dilated cardiomyopathy by strain echocardiography. J Am Soc Echocardiogr 2012; 25(6): 667-73.
[http://dx.doi.org/10.1016/j.echo.2012.02.004] [PMID: 22421028]
[55]
Wu KC, Weiss RG, Thiemann DR, et al. Late gadolinium enhancement by cardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy. J Am Coll Cardiol 2008; 51(25): 2414-21.
[http://dx.doi.org/10.1016/j.jacc.2008.03.018] [PMID: 18565399]
[56]
Zipes DP, Wellens HJJ. Sudden cardiac death. Circulation 1998; 98(21): 2334-51.
[http://dx.doi.org/10.1161/01.CIR.98.21.2334] [PMID: 9826323]
[57]
Zuo H, Zhang Y, Ma F, et al. Myocardial deformation pattern differs between ischemic and non-ischemic dilated cardiomyopathy: The diagnostic value of longitudinal strains. Ultrasound Med Biol 2020; 46(2): 233-43.
[http://dx.doi.org/10.1016/j.ultrasmedbio.2019.10.006] [PMID: 31718811]
[58]
Pi SH, Kim SM, Choi JO, et al. Prognostic value of myocardial strain and late gadolinium enhancement on cardiovascular magnetic resonance imaging in patients with idiopathic dilated cardiomyopathy with moderate to severely reduced ejection fraction. J Cardiovasc Magn Reson 2018; 20(1): 36.
[http://dx.doi.org/10.1186/s12968-018-0466-7] [PMID: 29898740]
[59]
Riffel JH, Keller MG, Rost F, et al. Left ventricular long axis strain: A new prognosticator in non-ischemic dilated cardiomyopathy? J Cardiovasc Magn Reson 2016; 18(1): 36.
[http://dx.doi.org/10.1186/s12968-016-0255-0] [PMID: 27268238]
[60]
Merlo M, Masè M, Vitrella G, et al. Usefulness of addition of magnetic resonance imaging to echocardiographic imaging to predict left ventricular reverse remodeling in patients with nonischemic cardiomyopathy. Am J Cardiol 2018; 122(3): 490-7.
[http://dx.doi.org/10.1016/j.amjcard.2018.04.017] [PMID: 29958711]
[61]
Romano S, Judd RM, Kim RJ, et al. Feature-tracking global longitudinal strain predicts death in a multicenter population of patients with ischemic and nonischemic dilated cardiomyopathy incremental to ejection fraction and late gadolinium enhancement. JACC Cardiovasc Imaging 2018; 11(10): 1419-29.
[http://dx.doi.org/10.1016/j.jcmg.2017.10.024] [PMID: 29361479]
[62]
Buss SJ, Breuninger K, Lehrke S, et al. Assessment of myocardial deformation with cardiac magnetic resonance strain imaging improves risk stratification in patients with dilated cardiomyopathy. Eur Heart J Cardiovasc Imaging 2015; 16(3): 307-15.
[http://dx.doi.org/10.1093/ehjci/jeu181] [PMID: 25246506]
[63]
Sutherland GR. Sudden cardiac death: the pro-arrhythmic interaction of an acute loading with an underlying substrate. Eur Heart J 2017; 38(40): 2986-94.
[http://dx.doi.org/10.1093/eurheartj/ehw449] [PMID: 28137981]
[64]
Yancy CW, Jessup M, Bozkurt B, et al. 2017 acc/aha/hfsa focused update of the 2013 accf/aha guideline for the management of heart failure: A report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart failure society of America. Circulation 2017; 136(6): e137-61.
[http://dx.doi.org/10.1161/CIR.0000000000000509] [PMID: 28455343]
[65]
Levine YC, Rosenberg MA, Mittleman M, et al. B-type natriuretic peptide is a major predictor of ventricular tachyarrhythmias. Heart Rhythm 2014; 11(7): 1109-16.
[http://dx.doi.org/10.1016/j.hrthm.2014.04.024] [PMID: 24837348]
[66]
Berger R, Huelsman M, Strecker K, et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002; 105(20): 2392-7.
[http://dx.doi.org/10.1161/01.CIR.0000016642.15031.34] [PMID: 12021226]
[67]
Winkler K, Wanner C, Drechsler C, Lilienthal J, März W, Krane V. Change in N-terminal-pro-B-type-natriuretic-peptide and the risk of sudden death, stroke, myocardial infarction, and all-cause mortality in diabetic dialysis patients. Eur Heart J 2008; 29(17): 2092-9.
[http://dx.doi.org/10.1093/eurheartj/ehn278] [PMID: 18617483]
[68]
Aimo A, Januzzi JL Jr, Vergaro G, et al. Prognostic value of high- sensitivity troponin t in chronic heart failure: an individual patient data meta-analysis. Circulation 2018; 137(3): 286-97.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.117.031560] [PMID: 29335288]
[69]
Vadakkumpadan F, Trayanova N, Wu KC. Image-based left ventricular shape analysis for sudden cardiac death risk stratification. Heart Rhythm 2014; 11(10): 1693-700.
[http://dx.doi.org/10.1016/j.hrthm.2014.05.018] [PMID: 24854217]
[70]
Levine YC, Matos J, Rosenberg MA, Manning WJ, Josephson ME, Buxton AE. Left ventricular sphericity independently predicts appropriate implantable cardioverter-defibrillator therapy. Heart Rhythm 2016; 13(2): 490-7.
[http://dx.doi.org/10.1016/j.hrthm.2015.09.022] [PMID: 26409099]
[71]
Sardu C, Marfella R, Santamaria M, et al. Stretch, injury and inflammation markers evaluation to predict clinical outcomes after implantable cardioverter defibrillator therapy in heart failure patients with metabolic syndrome. Front Physiol 2018; 9: 758.
[http://dx.doi.org/10.3389/fphys.2018.00758] [PMID: 29997521]
[72]
Binas D, Daniel H, Richter A, et al. The prognostic value of sST2 and galectin-3 considering different aetiologies in non-ischaemic heart failure. Open Heart 2018; 5(1): e000750.
[http://dx.doi.org/10.1136/openhrt-2017-000750] [PMID: 29531765]
[73]
McNally EM, Mestroni L. Dilated cardiomyopathy: genetic determinants and mechanisms. Circ Res 2017; 121(7): 731-48.
[http://dx.doi.org/10.1161/CIRCRESAHA.116.309396] [PMID: 28912180]
[74]
Jansweijer JA, Nieuwhof K, Russo F, et al. Truncating titin mutations are associated with a mild and treatable form of dilated cardiomyopathy. Eur J Heart Fail 2017; 19(4): 512-21.
[http://dx.doi.org/10.1002/ejhf.673] [PMID: 27813223]
[75]
Wahbi K, Ben Yaou R, Gandjbakhch E, et al. Development and validation of a new risk prediction score for life-threatening ventricular tachyarrhythmias in laminopathies. Circulation 2019; 140(4): 293-302.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.118.039410] [PMID: 31155932]
[76]
Lupón J, de Antonio M, Vila J, et al. Development of a novel heart failure risk tool: the barcelona bio-heart failure risk calculator (BCN bio-HF calculator). PLoS One 2014; 9(1): e85466.
[http://dx.doi.org/10.1371/journal.pone.0085466] [PMID: 24454874]
[77]
Pei J, Li N, Gao Y, et al. The J wave and fragmented QRS complexes in inferior leads associated with sudden cardiac death in patients with chronic heart failure. Europace 2012; 14(8): 1180-7.
[http://dx.doi.org/10.1093/europace/eur437] [PMID: 22308082]
[78]
Brembilla-Perrot B, Jacquemin L, Beurrier D. Relationships between heart rate variability and antiarrhythmic effects of hydroquinidine. Cardiovasc Drugs Ther 1997; 11(3): 493-8.
[http://dx.doi.org/10.1023/A:1007709808576] [PMID: 9310279]
[79]
Daubert JP, Winters SL, Subacius H, et al. Ventricular arrhythmia inducibility predicts subsequent ICD activation in nonischemic cardiomyopathy patients: A DEFINITE substudy. Pacing Clin Electrophysiol 2009; 32(6): 755-61.
[http://dx.doi.org/10.1111/j.1540-8159.2009.02362.x] [PMID: 19545338]
[80]
Gatzoulis KA, Vouliotis AI, Tsiachris D, et al. Primary prevention of sudden cardiac death in a nonischemic dilated cardiomyopathy population: reappraisal of the role of programmed ventricular stimulation. Circ Arrhythm Electrophysiol 2013; 6(3): 504-12.
[http://dx.doi.org/10.1161/CIRCEP.113.000216] [PMID: 23588627]
[81]
Goldberger JJ, Subačius H, Patel T, Cunnane R, Kadish AH. Sudden cardiac death risk stratification in patients with nonischemic dilated cardiomyopathy. J Am Coll Cardiol 2014; 63(18): 1879-89.
[http://dx.doi.org/10.1016/j.jacc.2013.12.021] [PMID: 24445228]
[82]
Abdelghani SA, Rosenthal TM, Morin DP. Surface electrocardiogram predictors of sudden cardiac arrest. Ochsner J 2016; 16(3): 280-9.
[PMID: 27660578]
[83]
Hannun AY, Rajpurkar P, Haghpanahi M, et al. Cardiologist-level arrhythmia detection and classification in ambulatory electrocardiograms using a deep neural network. Nat Med 2019; 25(1): 65-9.
[http://dx.doi.org/10.1038/s41591-018-0268-3] [PMID: 30617320]
[84]
Mincholé A, Rodriguez B. Artificial intelligence for the electrocardiogram. Nat Med 2019; 25(1): 22-3.
[http://dx.doi.org/10.1038/s41591-018-0306-1] [PMID: 30617324]
[85]
Kusumoto FM, Calkins H, Boehmer J, et al. HRS/ACC/AHA expert consensus statement on the use of implantable cardioverter-defibrillator therapy in patients who are not included or not well represented in clinical trials. Circulation 2014; 130(1): 94-125.
[http://dx.doi.org/10.1161/CIR.0000000000000056] [PMID: 24815500]
[86]
Arbustini E, Disertori M, Narula J. Primary prevention of sudden arrhythmic death in dilated cardiomyopathy: Current guidelines and risk stratification. JACC Heart Fail 2017; 5(1): 39-43.
[http://dx.doi.org/10.1016/j.jchf.2016.11.009] [PMID: 28034375]
[87]
Akhtar M, Elliott PM. Risk stratification for sudden cardiac death in non-ischaemic dilated cardiomyopathy. Curr Cardiol Rep 2019; 21(12): 155.
[http://dx.doi.org/10.1007/s11886-019-1236-3] [PMID: 31768884]
[88]
Halliday BP, Cleland JGF, Goldberger JJ, Prasad SK. Personalizing risk stratification for sudden death in dilated cardiomyopathy: The past, present, and future. Circulation 2017; 136(2): 215-31.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.116.027134] [PMID: 28696268]
[89]
Buxton AE, Waks JW, Shen C, Chen PS. Risk stratification for sudden cardiac death in North America - current perspectives. J Electrocardiol 2016; 49(6): 817-23.
[http://dx.doi.org/10.1016/j.jelectrocard.2016.07.018] [PMID: 27524476]
[90]
Daubert JP, Lewis RK. Smarter deployment of implantable cardioverter-defibrillators in nonischemic cardiomyopathy: feasible or mythical? J Am Coll Cardiol 2014; 63(18): 1890-1.
[http://dx.doi.org/10.1016/j.jacc.2013.12.022] [PMID: 24486276]

Rights & Permissions Print Cite
Article Metrics
20
1
© 2024 Bentham Science Publishers | Privacy Policy